Table 3. Treatment according to gender.
| Women | Men | P-value | |
| Pre-admission medications | |||
| β-blockers | 454 (18.4) | 1835 (12.9) | 0.001 |
| Calcium channel blockers | 239 (9.7) | 515 (3.6) | 0.001 |
| ACE/ARB | 447 (18.1) | 1413 (9.9) | 0.001 |
| Anti-platelet agents | 1239 (50.1) | 4299 (30.1) | 0.001 |
| On Admission | |||
| β-blockers | 1006 (40.7) | 7253 (50.9) | 0.001 |
| Calcium channel blockers | 404 (16.3) | 1007 (7.1) | 0.001 |
| ACE/ARB | 840 (34) | 4326 (30.3) | 0.001 |
| Anti-platelet agents | 2264 (91.5) | 13483 (94.5) | 0.001 |
| Heparin | 723 (29) | 5687 (40) | 0.001 |
| LMW Heparin | 535 (22) | 2630 (18) | 0.001 |
| Glycoprotein blocker | 77 (3) | 668 (5) | 0.001 |
| Thrombolysis | 285 (11.5) | 4469 (31) | 0.001 |
| Coronary angiography | 192 (8) | 1837 (13) | 0.001 |
| PTCA | 130 (5) | 999 (7) | 0.002 |
| Stent | 96 (4) | 655 (5) | 0.11 |
| At Discharge | |||
| β-blockers | 577 (23.3) | 4547 (31.9) | 0.001 |
| Calcium channel blockers | 539 (21.8) | 1456 (10.2) | 0.001 |
| Diuretics | 756 (30.6) | 2232 (15.6) | 0.001 |
| ACE/ARB | 993 (40.1) | 5722 (40.1) | 0.98 |
| Anti-platelet agents | 2046 (82.7) | 13019 (91.3) | 0.001 |
| Clopidogerl | 769 (31.1) | 4981 (34.9) | 0.001 |
| Aspirin | 2007 (81.1) | 12899 (90.4) | 0.001 |
| Statin | 1284 (52) | 7381 (52) | 0.90 |
ACE/ARB: Angiotensin converting enzyme inhibitor; PTCA: Percutaneous Coronary Angioplasty; All values in parenthesis are percentages.